Dapoxetine
From Wikipedia, the free encyclopedia
|
|
|
| (1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenyl -propan-1-amine IUPAC name |
|
| CAS number 119356-77-3 (base compound) 129938-20-1 (HCl salt) |
ATC code ? |
| PubChem 71353 |
DrugBank ? |
| Chemical formula | C21H23NO |
| Molecular weight | 305.413 g/mol |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | ? |
| Excretion | ? |
| Pregnancy category | ? |
| Legal status | Rx-only |
| Routes of administration | Oral |
Dapoxetine is the International Nonproprietary Name of a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. It is currently in Phase III of the approval process. This would make it join the ranks of sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®), the erectile dysfunction drugs and cabergoline (Dostinex®) (off-label), as a drug invented to improve male sexual health.
Dapoxetine, submitted to the FDA in the form of dapoxetine hydrochloride, was developed by ALZA Corporation and its parent company, Johnson & Johnson.
Like other drugs specifically targeted to treat premature ejaculation, it is controversial for turning something that is traditionally considered psychological into a physiological problem that can be treated, to the benefit of the pharmaceutical industry (but also of the people with the dysfunction).
In October of 2005, the FDA issued a "not approvable" letter for dapoxetine[1].
[edit] External links
- "Premature Ejaculation Drug Promising"
- "The many mysteries of the female orgasm" - An editorial about advances in sexual pharmacology
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
